The FDA says most doses of Eli Lilly’s Zepbound, Mounjaro were in short supply by June

Most doses Eli LillyHugely popular weight reduction drug Zepbound and diabetes drug Mounjaro will probably be in short supply in the second quarter of this yr resulting from a surge in demand, analysts say. update in the Food and Drug Administration’s drug shortage database.

All doses of Zepbound and Mounjaro except 2.5-milligram versions of each therapies are in short supply. AND previous update stated that the provision of some doses of each drugs will probably be limited in April.

A brand new update suggests that insatiable demand for the fashionable class of weight-loss and diabetes drugs continues to outpace supply, at the same time as Eli Lilly and its chief rival New Nordisk work to extend production of these treatments.

Many patients have difficulty finding high-demand injectable treatments that may help them lose significant weight over time. These therapies are sometimes called incretin drugs, which mimic gut hormones to suppress appetite and regulate blood sugar levels.

Eli Lilly didn’t immediately reply to a request for comment on Wednesday’s FDA update.

In February, Eli Lilly said it had met its goal of doubling production capability of such incretin drugs by the top of 2023. The company said it could increase production “as urgently” this yr, with the most significant increase coming in second half of 2023. yr.

By that time, the corporate expects production of sold doses of incretin drugs to be not less than 1.5 times higher than in the second half of 2023.

Eli Lilly also said a brand new plant in Concord, North Carolina, will begin producing incretin drugs as soon as the top of the yr, with products available for shipment in 2025. The company will even construct several other facilities over the following few years, including a headquarters in Germany and two latest factories in its home state of Indiana.

Novo Nordisk announced similar actions. Some doses of Novo Nordisk’s weight-loss drug Wegovy and diabetes drug Ozempic are also in short supply, in line with the FDA’s website.